Long-term Study of TAK-875.

Trial Profile

Long-term Study of TAK-875.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 May 2016

At a glance

  • Drugs Fasiglifam (Primary) ; Antihyperglycaemics
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational
  • Sponsors Takeda
  • Most Recent Events

    • 27 Dec 2013 Status changed from recruiting to discontinued, as reported by a Takeda media release.
    • 01 Nov 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 16 Sep 2011 New source identified and integrated (ClinicalTrials.gov record NCT01433406)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top